Themis Medicare Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹90 Cr +15.1% YoYSee revenue, profit and what management said. You are viewing Q1 FY26.
TM

Themis Medicare Ltd

Q1 FY26Pharmaceuticals & Biotechnology

Themis Medicare Q1 FY26: Revenue ₹97.58 Cr, PAT ₹14.22 Cr

Q1 FY26 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹98Cr
−20.7% YoY
+36.1% QoQ
Net profit
−₹14Cr
Q1 FY25: ₹25 Cr
Margin
−10.47%
−34.2 pp YoY
+0.3 pp QoQ

Based on Themis Medicare Ltd's Q1 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹118
Market cap₹1.1K Cr

The short version

Q1 FY26 Net Revenue: ₹97.58 Cr, down 20.7% year-on-year from ₹122.99 Cr in Q1 FY25 (Page 8). Q1 FY26 EBITDA: -₹10.08 Cr (negative 10.33% margin), down from ₹29.18 Cr (23.72% margin) in Q1 FY25, representing a 135% YoY decrease.

From Themis Medicare Ltd's Q1 FY26 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q1 FY26 Net Revenue: ₹97.58 Cr, down 20.7% year-on-year from ₹122.99 Cr in Q1 FY25 (Page 8).
  • Formulation Segment grew 35% quarter-on-quarter in Q1 FY26 (Page 8).
  • Revenue from Hospital business expanded 49% quarter-on-quarter in Q1 FY26 (Page 8).
  • Revenue from Trade business expanded 165% quarter-on-quarter in Q1 FY26 (Page 8).
  • API business showed 52% quarter-on-quarter growth in Q1 FY26 (Page 8).
  • Management expects a better bounce back in subsequent quarters with all strategic efforts gaining pace (Page 5).

2 more points from Themis Medicare Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Themis Medicare Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Related information includes: - Manufacturing Facilities: - Three state-of-art manufacturing sites located at Haridwar (Formulations), Hyderabad (Synthetic APIs), and Vapi (Synthetic APIs). - Capacities per annum: - Tablets: 520 million - Ointment tubes: 9 million - Ampoules: 36 million - Vials: 12 million - Pre-filled syringes: 6 million - Synthetic API capacities: 120 MT (Hyderabad) and 191 MT (Vapi) - R&D Investment: - Continued investments in R&D with yearly expenditure around Rs. 13-14 Cr (FY21 to FY25).

2 more points from Themis Medicare Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Themis Medicare Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Themis Medicare Ltd said on order book & pipeline — free account, 30 seconds.

Themis Medicare Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Themis Medicare Ltd Q1 FY26 results — key figures

Themis Medicare Ltd Q1 FY26 reported results vs Q1 FY25, ₹ crore
₹ CrQ1 FY26Q1 FY25YoYQ4 FY25QoQ
Revenue98123-20.7%72+36.1%
Operating profit (EBITDA)-1029-135%-8—
Operating margin-10.47%23.73%-34.2 pp-10.74%+0.3 pp
Profit before tax-1431-144.9%-11—
Net profit (PAT)-1425-157.6%-10—
EPS (₹)-1.542.68-157.5%-1.05—

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹90 Cr, net profit ₹7 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • RPG Life Sciences (Q1 FY26)

    168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

  • SMS Pharmaceuticals (Q1 FY26)

    Q1FY26 revenue from operations: ₹196.05 crore . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…

  • Morepen Laboratories (Q1 FY26)

    Crores)**: . Key concall takeaways from Morepen Laboratories Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

  • NGL Fine Chem (Q1 FY26)

    Q1FY26 Revenue from operations: ₹104.19 crores . Key concall takeaways from NGL Fine Chem Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Themis Medicare Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Themis Medicare Ltd Q1 FY26 results?

Q1 FY26 Net Revenue: ₹97.58 Cr, down 20.7% year-on-year from ₹122.99 Cr in Q1 FY25 (Page 8). Q1 FY26 EBITDA: -₹10.08 Cr (negative 10.33% margin), down from ₹29.18 Cr (23.72% margin) in Q1 FY25, representing a 135% YoY decrease.

What is Themis Medicare Ltd share price analysis?

Themis Medicare Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹1,142 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Themis Medicare Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.